TRIAD Pilot Projects Core
$298,802U19FY2012AINIH
University Of Rhode Island, Kingston RI
Investigators
Linked publications & trials
Paper 31629569Paper 26107442Paper 26090577Paper 26024663Paper 25629522Paper 25517089Paper 25385064Paper 25346775Paper 25346774Paper 25193104Paper 25157982Paper 25152768Paper 25111185Paper 24888712Paper 24823809Paper 24740005Paper 24721533Paper 24184517Paper 24122558Paper 24011240Paper 23877094Paper 23807079Paper 23732899Paper 23732897Paper 23722268Paper 23584251Paper 23514034Paper 23151160Paper 23076334Paper 23015495Paper 22814402Paper 22646824Paper 22130156Paper 22130151Paper 22130150Paper 22048119Paper 21708020Paper 21349362Paper 21236233Paper 21055490Paper 20706613Paper 20551718Paper 20431339Paper 20009527Paper 19616492Paper 19559119
Abstract
To meet the dual threats of emerging infectious diseases and engineered biowarfare/bioterror agents, there is a pressing need for more efficient systems for vaccine development. TRIAD, or the Translational Immunology Research and Accelerated [Vaccine] Development program, based in the Biotechnology Program at the University of Rhode Island, has pioneered the development and application of an integrated
View original record on NIH RePORTER →